1. Home
  2. REA vs TLSI Comparison

REA vs TLSI Comparison

Compare REA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rare Earths Americas Inc. Common Stock

REA

Rare Earths Americas Inc. Common Stock

N/A

Current Price

$10.16

Market Cap

232.3M

ML Signal

N/A

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

N/A

Current Price

$4.32

Market Cap

270.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REA
TLSI
Founded
N/A
2010
Country
United States
Employees
N/A
102
Industry
Metal Mining
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.3M
270.2M
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
REA
TLSI
Price
$10.16
$4.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
119.5K
231.6K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.57
$2.20
52 Week High
$17.84
$7.95

Technical Indicators

Market Signals
Indicator
REA
TLSI
Relative Strength Index (RSI) 27.43 54.71
Support Level N/A $4.32
Resistance Level $12.20 $4.39
Average True Range (ATR) 1.03 0.29
MACD -0.07 -0.01
Stochastic Oscillator 5.56 90.17

Price Performance

Historical Comparison
REA
TLSI

About REA Rare Earths Americas Inc. Common Stock

Rare Earths Americas Inc is an exploration stage company focused on advancing projects related to rare earth minerals. Its activities include evaluating mineralization and assessing the characteristics and economic potential of its assets. Its portfolio includes the Shiloh Project in Georgia, United States; the Alpha Project in Bahia, Brazil; and the Constellation Project in Minas Gerais, Brazil. It also holds additional early-stage exploration projects, including the Homer Project in Goiás, Brazil, and the Liberty Peak Project in Georgia, United States. The company has two reportable segments due to their geographical location: United States Mining Operations and Brazil Mining Operations.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: